B
Bullisch
Bullisch · 25%CV
$5.79
Szenariopreis
$6.990
+0.195 (+2.79%)Zum Schluss
Loading chart…
- Hoch
- 7.180
- Eröffnung
- 6.720
- Volumengewichteter Durchschnittskurs
- 6.94
- Volumen
- 320.23K
- Marktkap.
- —
- Tief
- 6.660
- Umsatz
- 2.22M
- EV/EBITDA, TTM
- -8.69
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
KI-Analyse of CapsoVision Inc (CV)
KaufenCapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position, and a 10% revenue growth in Q2 2026. The current price is $6.99, and the RSI is at 74.861, indicating strong momentum. However, the main risk is the negative net income of -7,481,000 USD reported in Q2 2026, which investors should consider.
Bewertungskennzahlen
Das aktuelle erwartete KGV von CapsoVision Inc (CV) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -10.86.
Alphio-AI-Kursszenarien für CV
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
5.009-28NASDAQ.COMCapsoVision Receives FDA Clearance for AI-Assisted Tool
9.009-28NASDAQ.COMCapsoVision Receives FDA Clearance for AI-Assisted Tool
9.508-14Yahoo FinanceCapsoVision Reports 10% Revenue Growth in Q2 2026
9.508-04NASDAQ.COMCRISPR Therapeutics Reports Narrowed Loss in Q2 2026
5.008-04NASDAQ.COMCapsoVision Launches AI Highlights for Capsule Endoscopy Studies
CV FAQ – beantwortet von Alphio AI
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule. It operates in the Healthcare sector.
CapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position, and a 10% revenue growth in Q2 2026. The current price is $6.99, and the RSI is at 74.861, indicating strong momentum. However, the main risk is the negative net income of -7,481,000 USD reported in Q2 2026, which investors should consider.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.